Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: GE stock price vs BIO: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BIO's multiple
Needs BIO P/E.
Implied fair value · at GE's multiple
Needs GE P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
14 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
GENERAL ELECTRIC CO · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
BIO-RAD LABORATORIES, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
MORGAN STANLEY
GE vs MS
EMERSON ELECTRIC CO
GE vs EMR
3M CO
GE vs MMM
CUMMINS INC
GE vs CMI
HONEYWELL INTERNATIONAL INC
GE vs HON
LOCKHEED MARTIN CORP
GE vs LMT
DANAHER CORP /DE/
GE vs DHR
ILLUMINA, INC.
GE vs ILMN
AGILENT TECHNOLOGIES, INC.
GE vs A
BIO-TECHNE Corp
GE vs TECH
BRUKER CORP
GE vs BRKR
Azenta, Inc.
GE vs AZTA
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe GE's 18.5% revenue growth and 31.4% ROIC can persist, then hold or accumulate selectively despite the valuation premium, because GE's operating quality is far stronger than BIO's; if you focus primarily on relative multiples, the stock looks expensive versus BIO and BIO-implied valuation.
GE trades at a steep premium to BIO on both earnings and revenue-based multiples, which is why the simple P/E implied value points to significant downside. However, GE also has materially stronger growth and returns, so the valuation gap is not purely a sign of overvaluation without considering business quality.
Supporting Metrics
